Eosinophilic asthma (e-asthma) is a rare form of the breathing disease that can be very hard to treat successfully. That can put you in a frustrating cycle of asthma attacks. People with e-asthma are ...

Michael E. Wechsler, MD, a pulmonologist at National Jewish Health, discusses the challenges associated with differentiating similar eosinophilic conditions, including eosinophilic asthma, from one ...

Michael E. Wechsler, MD, a pulmonologist at National Jewish Health, details the ways that the treatment of eosinophilic asthma differs from other forms of asthma. So, what we've come to recognize is ...

Cam Heyward explains how he manages asthma as a Steelers star and why he wants fans to ask doctors about a simple blood test for more severe eosinophilic asthma. The post Steelers’ Cam Heyward Raises ...

Some people with very severe asthma symptoms have a condition called eosinophilic asthma. People with this type of asthma may need to use inhaled medicines along with a newer type of medicine that is ...

Please provide your email address to receive an email when new articles are posted on . Benralizumab induces depletion of eosinophils and mepolizumab reduces activation. The study followed patients ...

Pharmaceutical company AstraZeneca has launched a website that provides information on eosinophilic asthma, a severe form of the disease. The site, AsthmaBehavingBadly.com, features cartoon depictions ...

Dupilumab (interleukin-4Rα; antibody binds to interleukin-4Rα, inhibiting interleukin-4 and interleukin-13 signaling in hematopoietic cells [e.g., B cells, CD4+ helper T cells, and eosinophils], ...

AnaptysBio specializes in the development of antibody-based therapeutics for the management of inflammation and allergy. Pipeline is broad to give more “shots on goal” of finding a blockbuster.

Please provide your email address to receive an email when new articles are posted on . Women with asthma outnumber men by about 3 to 1. Asthma encounters accounted for 4% of ED and inpatient visits.

AstraZeneca experienced some setbacks last year on its quest to expand its asthma drug Fasenra to treat other conditions like rhinosinusitis and eosinophilic esophagitis. However, the British pharma ...